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PODIUM SESSION I: HEALTH CARE DECISION-MAKER’S
CASE STUDIES I
CASE1
LESSONS LEARNED: FROM COVERAGE WITH EVIDENCE
DEVELOPMENT FOR POSITRON EMISSION TOMOGRAPHY 
SCANS FOR ONCOLOGIC INDICATIONS
Whicher DM, Tunis S
Center for Medical Technology Policy, Baltimore, MD, USA
ORGANIZATION: The Centers for Medicare and Medicaid Services (CMS).
PROBLEM OR ISSUE ADDRESSED: In 2005, CMS issued a national coverage deter-
mination for Positron Emission Tomography (PET) for oncologic indications not previ-
ously covered by Medicare, which provided payment for PET scans for these indications 
only in the context of an approved prospective clinical trial designed to assess clinical 
utility of PET. CMS instated this policy option, referred to as ‘Coverage with Evidence 
Development’ (CED), due to the lack of evidence demonstrating the clinical effective-
ness of PET scans for patient management, which is necessary to determine whether 
PET scans are reasonable and necessary for the diagnosis, staging, re-staging, and 
monitoring of various cancer types. CED allowed CMS to guide evidence development 
while providing access to this potentially beneﬁ cial technology. GOALS: To determine 
whether PET imaging is clinically effective for previously uncovered oncologic indica-
tions. OUTCOMES ITEMS USED IN THE DECISION: The main outcomes were 
change in intended management strategy and whether the PET scan allowed physicians 
to avoid other tests or procedures. Based on these, Medicare’s Evidence Development
and Coverage Advisory Committee (MEDCAC) members had to decide how conﬁ dent 
they were that PET improves physician decision-making and clinical outcomes, and 
that the conclusions were generalizable to other cancers, to PET facilities in the general 
community, and to the Medicare population. IMPLEMENTATION STRATEGY: Since
CMS did not have the capacity to design and fund a study, the agency partnered with
the American College of Radiology and the Academy of Molecular Imaging. The study 
itself had to be implemented within a short time do to federal regulations. The registry 
began patient and physician registration in May of 2006. This design was chosen in
part because it balanced the desire for access to this service with the goal of generating 
evidence of reasonable quality that could be used by CMS to make a ﬁ nal coverage
determination. RESULTS: After the ﬁ rst year, most PET facilities in the United States
had signed up to participate in the registry and a huge nationwide sample of data had
been collected. The results from this data analysis demonstrate that physicians report 
a change in intended disease management strategy in about one out of every three cases 
and that when broken down by disease cancer type and indication, the ﬁ gure remains 
fairly constant (Hillner et al. 2008). This evidence was reviewed in August 2008 at a 
meeting of MEDCAC. Based on these results and the results of a health technology
assessment, MEDCAC members were asked to rate their conﬁ dence in the clinical
utility of PET and the generalizability of the conclusions. The ratings demonstrated
that MEDCAC members have limited conﬁ dence that PET improves clinical outcomes
based on the evidence. Members pointed out that although the results show that physi-
cians often change their intended management plan, there is no way to know if actual
management changed and even if it did, it is also not known whether these changes
actually lead to better patient outcomes. Still, on January 6, 2009, CMS issued a deci-
sion memo stating that there is now sufﬁ cient evidence showing that PET improves
health outcomes when used for the diagnosis and staging of all previously uncovered
cancer types, warranting coverage for these indications. However, CMS does not
believe that there is enough evidence demonstrating the clinical utility of PET for 
monitoring response to treatment and re-staging. Therefore, these indications will still 
only be covered through the CED policy, likely necessitating the development of a new
prospective study. LESSONS LEARNED: The case presented above not only demon-
strates that CED is operationally and technically possible while abiding to regulatory 
procedures, it also demonstrates CED can be used to help support research efforts 
designed to address questions of importance to health care decision-makers. In addi-
tion, as this is one of the ﬁ rst examples of Medicare taking advantage of CED, it also 
offers some lessons for the future. For instance, in order to streamline the process, it 
is necessary to identify a stable source of funding for these projects, to identify promis-
ing technologies which lack evidence of clinical effectiveness earlier in the development 
process, to reach a shared understanding among stakeholders of standards of evidence 
that are feasible and sufﬁ ciently robust for coverage decisions, and to reach a consensus
as to the most efﬁ cient methods for conducting real world trials. In the future, it would
be best if decisions of study design did not take place while Medicare was making a 
coverage determination and if private payers became involved in CED so a broader
range of patients could participate in the studies.
CASE2
TOWARDS AN INTEGRATED APPROACH TO THE ASSESSMENT
OF SURROGATE OUTCOME DATA
Platona A, Lopert R, Sansom L
Department of Health and Ageing, Canberra, ACT, Australia
ORGANIZATION: The Pharmaceutical Beneﬁ ts Advisory Committee (PBAC) is a
statutory independent expert committee which makes recommendations to the 
Australian Government on medicines to be listed on the national reimbursement
formulary (Pharmaceutical Beneﬁ ts Scheme). PROBLEM OR ISSUE ADDRESSED:
The proportion of regulatory and reimbursement applications in which the efﬁ cacy
assessment is limited to surrogate outcome data is increasing. Pressure to bring 
products to market quickly and facilitate access by patients to new treatments, as
well as the costs and time involved in conducting clinical endpoint trials, has led to
increasing reliance on these data. While substantial activity is focused on methodo-
logical, mainly statistical, approaches to the validation of surrogate outcomes, the
determination of the magnitude of absolute or comparative treatment beneﬁ t offered 
by new medicines must be made by regulatory and reimbursement decision makers 
even where validity has not been clearly demonstrated. GOALS: To highlight the 
need for a more coordinated approach to clinical trial design and the assessment
of outcome data by regulatory and reimbursement agencies with respect to reliance 
on surrogate outcomes. OUTCOMES ITEMS USED IN THE DECISION:
IMPLEMENTATION STRATEGY: In late 2007, the PBAC established a multi-
disciplinary working group which included representatives from the PBAC and its 
Economics Sub-Committee, and the Australian regulator (the Therapeutic Goods 
Administration), as well as external experts, and representatives of the pharmaceutical
industry with the objective of identifying recent developments, policy and method-
ological, with respect to surrogate outcome data. RESULTS: One of the more complex
issues encountered during the comparative effectiveness and comparative cost effec-
tiveness assessment of medicines is the determination of the incremental treatment
effect when the available evidence is limited to surrogate outcome data. Reimburse-
ment decision-makers attempting to determine incremental cost effectiveness must 
not only identify any qualitative difference in treatment effect, this must also be mea-
sured and valued for incorporation into cost effectiveness analysis. Where clinical 
beneﬁ t is only demonstrated against a surrogate endpoint and where the validity 
of that surrogate endpoint is uncertain, the relationship between a change in the
surrogate and a change in the ﬁ nal clinical endpoint will also be uncertain. Despite 
much analysis and deliberation the working group was unable to identify a deﬁ nitive 
strategy for evaluating a surrogate outcome data in the context of an economic 
evaluation, but acknowledged that the transformation of surrogates outcomes into
ﬁ nal outcomes is associated with signiﬁ cant and extensive uncertainty which can sub-
stantively impact on the capacity of decision makers to make robust determinations
of comparative cost effectiveness. This difﬁ culty and uncertainty could be reduced 
through greater, earlier and more systematic collaboration between regulators and
funders, and coordinated engagement with the developers of new products. Although
formal cooperation agreements exist between a number of regulatory agencies, formal 
relationships between regulators such as the EMEA and any of the European 
HTA/reimbursement agencies, such as the UK’s National Institute for Health and 
Clinical Excellence (NICE), for the joint identiﬁ cation, evaluation and validation of 
surrogate endpoints, and the determination of the signiﬁ cance accorded to them in
the regulatory and reimbursement decision-making process, do not appear to exist.
LESSONS LEARNED: Regulators evaluating medicines for marketing approval pro-
cesses are not the only decision makers who rely on the results of randomised trials. 
The commercial success of a new medicine is increasingly dependent on a successful 
reimbursement approval, and this often means signiﬁ cant public investment. Ideally
regulatory-reimbursement collaboration should occur in the design phase of clinical 
trials so that endpoints that are meaningful, measurable and relevant to both regula-
tors and funders are identiﬁ ed and utilised. Policy makers currently debating the 
establishment of a framework for comparative effectiveness research in the United 
States may also wish to engage in the debate around the identiﬁ cation, selection and 
validation of surrogate endpoints as this will be essential to the meaningful interpreta-
tion of these comparative analyses. Overall, the role of multiple decision makers in
the process from drug development to drug subsidy and the need for better coordina-
tion is a very important one.
CASE3
HEALTH SERVICES PHARMACEUTICAL COVERAGE FOR
COMMON DISEASES MAY BE CHALLENGED BY SIGNIFICANT 
RISE IN ONCOLOGY DRUG EXPENDITURE
Katzir I, Westerman-Landes J, Siegelmann-Danieli N, Kokia E, Lomnicky Y
Maccabi Healthcare Services, Tel Aviv, Israel
ORGANIZATION: Maccabi Healthcare Services. PROBLEM OR ISSUE 
ADDRESSED: Health Care Services face the challenges of accommodating modern 
therapies in the face of rising costs for newly developed drugs. Maccabi Health Services 
(MHS) is an leading Israeli health organization known for an early adoption of newly 
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approved therapies for its beneﬁ ciaries far advancing the national health basket. 
GOALS: The current work describes trends in MHS medication use and expenditures
over the last decade. OUTCOMES ITEMS USED IN THE DECISION: Total number
of packages dispensed per beneﬁ ciary, total drug expenditure. IMPLEMENTATION
STRATEGY: The MHS database was explored to identify trends in medication 
use and expenditures during the years 1998 to 2007. Expenditures were matched to 
the Israeli 2007 cost-of health living. Eight major pharmacological groups accounted
for half of the costs and were further detailed: antibiotics (representing “acute
therapy”), oncology drugs (for “severely ill”), cardiovascular, diabetic, lipid lowering
drugs and anti-depressive medications (for “chronic patients”), and medication to
treat migraine and asthma (“seasonal” therapies). RESULTS: During the study period 
MHS beneﬁ ciaries increase by 34.5% up to 1.74 million people. In this period rise of 
23% in total number of packages dispensed per beneﬁ ciary was noted. The most
noticeable rise in this parameter was noted in hypo-lipemic agents (394%), while the
most noticeable drop was noted in antibiotics (21%). In between, a rise of 84% was 
noticed on anti-neoplastic agents. During this period, 62% rise in total drug expendi-
ture (21% after correction for increased number of beneﬁ ciaries) was observed. The 
relative share of expenses of the 8 pharmacological groups was signiﬁ cantly changed,
with most noticeable rise of 454% in anti-neoplastic agents and 60% drop in antibiot-
ics. The total expenses on hypol-ipemic agents rose by 72%. LESSONS LEARNED:
The signiﬁ cant rise in medications use and expenses during the study period reﬂ ects 
changes in several parameters such as more aggressive treatment targets, better educa-
tion of physicians and patients, implementation of pre-authorization techniques and
introduction of newly developed, expensive medications. If continues, the dramatic 
rise in the share of expenses on anti-neoplastic drugs in MHS, as in other health care
givers in developed countries, could become a threat to the public health funding,
who’s budgets are limited, but in the long run could threat the drug manufacturers as
well. Discussions between health care givers, regulatory authorities and drug manu-
facturers in order to agree upon “rules of play” reﬂ ecting mutual interests are neces-
sary to resolve this threat.
PODIUM SESSION I: CANCER – Outcomes Research Studies
CN1
RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA)
UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A
MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING
Lafeuille MH1, Bailey R2, Vekeman F1, Piech CT2, McKenzie RS2, Lefebvre P1
1Groupe d’Analyse, Ltée, Montréal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA
OBJECTIVES: With recent changes in ESA prescribing information and coverage
limitations, this study evaluated current epoetin alfa (EPO) and darbepoetin alfa 
(DARB) real-world utilization in cancer chemotherapy patients in two different large, 
US outpatient settings. METHODS: Medical claims from the Ingenix IMPACT 
Managed Care and PREMIER Perspective Comparative Hospital databases, between 
2006Q1–2007Q4 were analyzed. Patients were q18 years old, had q1 cancer diagno-
sis, newly initiated on EPO or DARB with q2 doses of either drug as outpatients, and
received chemotherapy during ESA treatment. Mean cumulative dose was used to 
assess impact of ESA prescribing information changes on drug utilization over time. 
The EPO : DARB dose ratio was calculated from the mean cumulative dose of EPO
and DARB. RESULTS: A total of 16,555 ESA treatment episodes (IMPACT:9,301; 
PREMIER:7,259) were identiﬁ ed. Patients receiving EPO were slightly older in 
IMPACT (EPO: 58.4 years; DARB: 56.3 years, p  0.0001) and slightly younger in 
PREMIER (EPO: 62.7 years; DARB: 64.0 years, p  0.0001), compared to DARB. A 
lower proportion of women was observed for the EPO groups (IMPACT: 64.2% vs.
68.4%; PREMIER: 62.2% vs. 65.4%, p  0.05 for both). The overall cumulative dose
per treatment episode was EPO 317,954 Units and DARB 1,238 mcg for IMPACT 
and EPO 263,582 Units and DARB 1,005 mcg for PREMIER, corresponding to
similar dose ratios of 257:1 and 262:1 for the managed care and hospital outpatient 
settings, respectively. Over time, mean treatment duration and cumulative ESA dose 
presented a downward trend for both EPO and DARB groups in both settings, with
dose ratios decreasing from 258:1 to 227:1 in IMPACT and from 279:1 to 209:1 in
PREMIER between 2006Q1 and 2007Q4. CONCLUSIONS: This study of cancer 
patients receiving chemotherapy in two outpatient settings reported decreased ESA 
utilization and EPO: DARB dose ratios following recent changes to ESA prescribing 
information and coverage.
CN2
WHEN IS CANCER CARE COST-EFFECTIVE? A SYSTEMATIC
OVERVIEW OF COST-UTILITY ANALYSES IN ONCOLOGY
Greenberg D1, Earle C2, Fang C1, Eldar-Lissai A3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Sunnybrook Health Sciences Centre, Toronto, ON, 
Canada, 3University of Rochester, Rochester, NY, USA
OBJECTIVES: New cancer treatments pose a substantial ﬁ nancial burden on patients,
their families, and society as a whole. Cost-utility analyses (CUAs) provide necessary 
information on the value for money and are widely published in the medical and
economic literature. We describe the growth over time of cancer-related CUAs 
and investigate whether methodological quality has improved. METHODS: We sys-
tematically searched the English-language literature for original cancer-related CUAs 
published through 2006 using Medline and other databases. Two trained readers
independently audited each study and collected data on a variety of elements related
to study origin, methods, and reporting of results. RESULTS: We identiﬁ ed 200 cancer-
related CUAs (currently included in the Tufts Medical Center Cost-Effectiveness 
Analysis Registry; www.cearegistry.org). The average annual number of studies has 
increased from 7 during 1988–2001 to 22 during 2002–2006. Leading sites studied
were breast (34%), colorectal (12%), and hematological (12%) cancers. Studies
have pertained to the U.S. (53%) U.K. (10%), The Netherlands (8%), and Canada 
(7%) and examined interventions for tertiary care (71%), secondary prevention
(22%), and primary prevention (7%). The pharmaceutical industry funded 25%
of studies, 41% were funded by non-industry sources and 32% did not disclose
any funding source. The median reported cost-effectiveness ratio (2007 values) 
was $32,000 for breast cancer, $17,000 for colorectal cancer, and $39,500 for hema-
tological cancers. Although adherence to recommended methods has somewhat 
improved in recent years, the average quality of studies (on a 1–7 Likert scale) 
was 4.2(o 1.1) and did not change substantially. CONCLUSIONS: The economic 
impact of cancer related interventions has received increased attention in the medical 
literature due to the very high cost of many newer cancer drugs. The lack of change 
in the quality of published studies suggests that journals should adopt a more rigorous
review to help ensure that authors adhere to guidelines for conducting and reporting 
CUAs.
CN3
ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH 
CARE COSTS ASSOCIATED WITH COLORECTAL CANCER
Rahman M1, Weinstein R2, Wilcox M2, Matcho A2, Wong S1
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2PRD USA, Titusville, NJ, USA
OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those 
costs, associated with an incident diagnosis of colorectal cancer (CRC). METHODS:
An analysis of incident CRC patients identiﬁ ed using a claims database, was per-
formed, for 2005, 2006, and 2007. CRC patients and the age and gender matched
comparator group (1:4) for each year, were required to have continuous enrollment 
in a plan and no CRC diagnoses during the 18 months prior to the ﬁ rst diagnosis 
of CRC in the year. The CRC and comparison groups were each described in terms 
of their health care service use and health care costs, which were compared, using
nonparametric Wilcoxon rank-sum tests, with mean values reported here for 2007. 
RESULTS: There were 13,673 patients diagnosed with CRC in 2007, in this database,
and we selected 54,688 controls. The mean health care cost for these patients 
diagnosed with CRC was $36,558 vs. $6,407 for controls; p  0.001. The primary 
drivers for this nearly 6 times greater cost difference between the 2 groups were: hos-
pitalizations ($15,996 vs. $1,959; p  0.001); prescription drugs ($6,689 vs. $1,382; 
p  0.001); radiology tests ($2,312 vs. $333; p  0.001); and physician visits ($1,665 
vs. $617; p  0.001). Resource utilization over the 12-month period showed that 
the patients with CRC, when compared to the control group, had a signiﬁ cantly
greater (p  0.001) mean number of hospitalizations (0.9 vs. 0.2); prescriptions drugs 
(33 vs. 17); radiology tests (9 vs. 2); and physician visits (12 vs. 7). The results were
similar for analyses conducted on 2006 and 2005 data. CONCLUSIONS: The signiﬁ -
cantly higher 12-month resource utilization and health care costs noted in patients
diagnosed with CRC, compared to age and gender matched controls, are primarily
driven by an increased need for hospitalizations, prescription drugs, radiology tests, 
and physician visits.
CN4
LEVERAGING MULTIPLE DATA SOURCES TO EVALUATE COST AND
SURVIVAL IN FOLFOX OR FOLFIRI TREATED STAGE IV COLORECTAL 
CANCER PATIENTS
Harley C1, Seal B2, Shetty S3
1i3 Innovus, Eden Prairie, MN, USA, 2Sanoﬁ -Aventis, Bridgewater, NJ, USA, 3UnitedHealthcare, 
Edina, MN, USA
OBJECTIVES: The trade-off between cost and mortality among stage IV colorectal 
cancer patients treated with 5FU/leucovorin/oxaliplatin (FOLFOX) or 5FU/leucovo-
rin/irinotecan (FOLFIRI) was examined. Multiple linked data sources were necessary
to obtain treatment, cancer stage, cost, and mortality. METHODS: Adults with 
colorectal cancer newly treated with FOLFOX or FOLFIRI were identiﬁ ed from a 
claims database for services January 1, 2002-December 31, 2005. Privacy board
approval for waiver of patient consent was obtained, and cancer stage was abstracted
from medical records; death was obtained from the National Death Index. Once 
matched, 41 FOLFOX and 86 FOLFIRI patients had stage IV cancer and were
retained. Costs were analyzed using generalized linear modeling; mortality was 
modeled using Cox proportional hazards analysis. Both controlled for age, gender, 
region, comorbidities, and treatment (biologic use, surgery, radiation). Sensitivity
analysis of cost was performed to adjust for availability of generic irinotecan in 2008.
Relative value of FOLFOX and FOLFIRI was measured by an incremental cost-effec-
tiveness ratio (ICER). Conﬁ dence intervals were estimated by bootstrapping with 1000 
replications. RESULTS: Unadjusted annualized mean cost was $152,213 (95% conﬁ -
dence interval [CI]: $113,547–$190,878) for FOLFOX, $107,994 (95% CI: $92,356–
$123,632) for FOLFIRI. Death occurred among 5 (12%) FOLFOX and 42 (53%) 
FOLFIRI patients. Adjusted analysis found no statistical difference in cost between 
cohorts. Cox analysis found signiﬁ cant survival advantage for FOLFOX compared to
FOLFIRI (Hazard ratio  5.2; 95% CI: 1.7–15.8). Biologic agent use was higher in 
the FOLFOX cohort and was associated with survival. ICER found one additional 
life-year saved was $1,236 (95% CI $300–$2350) with FOLFOX compared to 
